Table 2. Clinical course by adjuvant therapy methods.
| Parameters | Radiotherapy (n=25) | Chemotherapy (n=34) | p | ||
|---|---|---|---|---|---|
| Age (yr) | 63.8±8.8 | 62.8±6.5 | 0.631 | ||
| Body mass index (kg/m2) | 24.6±4.2 | 25.3±2.9 | 0.495 | ||
| Serum CA-125 level (IU/mL) | 27.0±22.6 | 23.7±18.4 | 0.543 | ||
| Postoperative histology | 0.085 | ||||
| Serous papillary | 20 (80.0) | 20 (58.8) | |||
| Clear cell | 5 (20.0) | 14 (41.2) | |||
| Concordance between preoperative and postoperative histologic results | 0.549 | ||||
| No | 13 (52.0) | 15 (44.1) | |||
| Yes | 12 (48.0) | 19 (55.9) | |||
| MI ≥1/2 | 0.160 | ||||
| No | 14 (56.0) | 25 (73.5) | |||
| Yes | 11 (44.0) | 9 (26.5) | |||
| LVSI | 0.200 | ||||
| No | 20 (80.0) | 22 (64.7) | |||
| Yes | 5 (20.0) | 12 (35.3) | |||
| Malignant cells in WC (n=52) | >0.999 | ||||
| No | 22 (95.7) | 27 (93.1) | |||
| Yes | 1 (4.3) | 2 (6.9) | |||
| Approach of radiotherapy | - | ||||
| Brachytherapy | 2 (8.0) | - | |||
| EBRT | 23 (92.0) | - | |||
| EBRT with brachytherapy | 0 | - | |||
| Concurrent chemotherapy with cisplatin | - | ||||
| No | 12 (48.0) | - | |||
| Yes | 13 (52.0) | - | |||
| Platinum based chemotherapy | - | ||||
| No | - | 1 (2.9) | |||
| Yes | - | 33 (97.1) | |||
| Cycles of chemotherapy (cycles) | - | ||||
| <6 | - | 17 (50.0) | |||
| ≥6 | - | 17 (50.0) | |||
| Recurrence | 0.891 | ||||
| No | 21 (84.0) | 29 (85.3) | |||
| Yes | 4 (16.0) | 5 (14.7) | |||
| Regional | 0 | 3 | |||
| Distant | 4 | 2 | |||
| Mean time to recurrence | 18.0±11.2 | 13.8±3.7 | 0.518 | ||
| Death | 0.386 | ||||
| No | 21 (84.0) | 32 (94.1) | |||
| Yes | 4 (16.0) | 2 (5.9) | |||
| Mean time to death | 23.0±12.5 | 35.6±22.6 | 0.354 | ||
The values are presented as the median (range) or number (%), unless otherwise indicated.
CA-125, cancer antigen-125; EBRT, external beam radiation therapy; LVSI, lymphovascular space invasion; MI, myometrial invasion; WC, washing cytology.